EDGAR Filing Documents for 0001140361-23-034885

Form 8-K - Current report:

SEC Accession No. 0001140361-23-034885

Filing Date

2023-07-18

Accepted

2023-07-18 08:05:14

Documents

Period of Report

2023-07-13

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Interactive Data

Document Format Files

Seq	Description	Document	Type	Size
1	8-K	brhc20055909_8k.htm iXBRL	8-K	40338
2	EXHIBIT 10.1	brhc20055909_ex10-1.htm	EX-10.1	332719
3	EXHIBIT 10.2	brhc20055909_ex10-2.htm	EX-10.2	158393
4	EXHIBIT 10.3	brhc20055909_ex10-3.htm	EX-10.3	109536
5	EXHIBIT 10.4	brhc20055909_ex10-4.htm	EX-10.4	198954
	Complete submission text file	0001140361-23-034885.txt		1139898

Data Files

Seq	Description	Document	Type	Size
6	XBRL TAXONOMY EXTENSION SCHEMA	erna-20230713.xsd	EX-101.SCH	3865
7	XBRL TAXONOMY EXTENSION LABEL LINKBASE	erna-20230713_lab.xml	EX-101.LAB	22546
8	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE	erna-20230713_pre.xml	EX-101.PRE	16044
10	EXTRACTED XBRL INSTANCE DOCUMENT	brhc20055909_8k_htm.xml	XML	4238

Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127

Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (212) 582-1199

Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)